Alpha Profiles · Company Profile

Addex Therapeutics Ltd.

https://registry.alpha.ac/companies/addex-therapeutics-ltd

Entity: Public listing published
Primary listing: NASDAQ: ADXN
Verification: Partially verified
Last reviewed: 2026-09-13T04:47:17.357268+00:00

Overview

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia;

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

2 public records

Roger Mills

Chief Medical Officer and Director

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-062447May 15, 2026

Tim Dyer

Chief Executive Officer and Director

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC 20-F 0001104659-26-062447May 15, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Sep 13, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.